Author:
Lavhale Pallavi Manish,Kesharwani Payal,Kumar Anoop,Prajapati Shiv Kumar
Publisher
Springer Nature Singapore
Reference69 articles.
1. Advani SH, Doval DC, Koppikar SB, Vijay Anand Reddy P, Prasad SV, Bapna A, Narayanan P, Dwary AD, Krishna V, Dhanushkodi M, Joel A (2021) Use of bevacizumab in advanced ovarian cancer: consensus from an expert panel oncologists. Indian journal of. Gynecol Oncol 19:1–8
2. Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K (2013) Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev 2:CD008765
3. Alnahar S, Elliott RA, Smith MD (2017) Biosimilar uptake by British local formularies: a cross sectional study. Int J Clin Pharm 39:1055–1060
4. Amneal Pharmaceuticals, Inc. Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States. (2023). https://investors.amneal.com/news/press-releases/press-release-details/2022/Amneal-Launches-First-Biosimilar-with-ALYMSYS-bevacizumab-maly-in-the-United-States/default.aspx. Accessed 19 Dec 2013
5. Bergandi L, Canosa S, Carosso AR, Paschero C, Gennarelli G, Silvagno F, Benedetto C, Revelli A (2020) Human recombinant FSH and its biosimilars: clinical efficacy, safety, and cost-effectiveness in controlled ovarian stimulation for in vitro fertilization. Pharmaceuticals 13(7):136